Searched over 200M research papers
10 papers analyzed
Some studies suggest losartan and valsartan are equally effective in lowering blood pressure with similar tolerability, while other studies indicate valsartan may have superior efficacy and additional cardiovascular benefits.
19 papers analyzed
Angiotensin II receptor blockers (ARBs) are a class of medications commonly used to manage hypertension. Among these, losartan and valsartan are frequently prescribed. This article synthesizes research comparing the efficacy and tolerability of losartan and valsartan in treating mild to moderate essential hypertension.
Multiple studies have demonstrated that both losartan and valsartan effectively reduce blood pressure in patients with mild to moderate hypertension. In a 12-week randomized trial, both drugs significantly lowered sitting diastolic blood pressure (SiDBP) from baseline, with losartan reducing SiDBP by 9.9 mm Hg and valsartan by 10.1 mm Hg, showing no significant difference between the two. Another study confirmed these findings, noting that both medications produced similar reductions in mean blood pressures at 4 and 8 weeks.
While both medications are effective, some studies suggest differences in response rates and consistency. Valsartan was found to have a higher responder rate (62%) compared to losartan (55%) at the 8-week endpoint. Additionally, valsartan demonstrated a more consistent antihypertensive effect across patients, as indicated by a smaller variability in blood pressure changes and a higher smoothness index.
ABPM studies provide a more detailed picture of blood pressure control over 24 hours. Research using ABPM showed that both losartan and valsartan significantly reduced systolic and diastolic blood pressures throughout the day. However, valsartan exhibited a smoother and more consistent blood pressure-lowering effect compared to losartan .
In patients with untreated essential hypertension and concentric left ventricular hypertrophy (LVH), valsartan was more effective than losartan in reducing left ventricular mass index (LVMi). Both drugs improved midwall systolic performance and left ventricular diastolic function, but the reduction in LVMi was significantly greater with valsartan.
When combined with amlodipine, valsartan showed superior efficacy compared to losartan. In a study where patients were inadequately controlled by amlodipine alone, the addition of valsartan resulted in greater reductions in both systolic and diastolic blood pressures compared to the addition of losartan.
Both losartan and valsartan are generally well-tolerated. Common adverse events include headache and dizziness, with no significant differences in the incidence of these events between the two drugs. However, losartan has the added benefit of significantly lowering serum uric acid levels, which was not observed with valsartan .
In summary, losartan and valsartan are both effective and well-tolerated options for treating mild to moderate hypertension. While their overall efficacy in blood pressure reduction is comparable, valsartan may offer advantages in terms of response rates, consistency of blood pressure control, and effectiveness in reducing left ventricular hypertrophy. Losartan, on the other hand, has the unique benefit of lowering serum uric acid levels. The choice between these two ARBs may ultimately depend on individual patient characteristics and specific clinical goals.
Most relevant research papers on this topic